I-Mab

168 articles about I-Mab

• I-Mab Biopharma Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Three Bispecific Antibody Programs

  9/26/2018

  WuXi Biologics will also be the exclusive partner to develop and manufacture these bispecifics.

• I-Mab Wins Frost & Sullivan "2018 Best R&D Innovator Award (Biopharma Category)"

  9/19/2018

  I-Mab Biopharma announced today that it has been recognized by Forest & Sullivan, the global leading growth consulting company as well as the biggest growth consulting company in China, with the "2018 Best R&D Innovator (Biopharma Category)" award.

• I-Mab's Announces China Clinical Trial Approval of Long-acting hGLP-1 to Treat Type 2 Diabetes

  8/9/2018

  In July, 2018, I-Mab Biopharma (I-Mab) announced that it received clinical trial approval from China National Drug Administration (CNDA) for TJ103 (TG103) injection: an innovative, humanized, long-acting recombinant glucagon-like peptide-1 (hGLP-1) fused with a hybrid Fc (hyFc) for type 2 diabetes treatment

• I-Mab Biopharma and MorphoSys Announce China IND Submission of TJ202/MOR202

  8/8/2018

  On August 8, 2018 Beijing time I-Mab Biopharma and MorphoSys AG announced today that I-Mab has Submitted an investigational new drug (IND) application to China National Drug Administration (CNDA) for TJ202/MOR202, a human monoclonal antibody directed against CD38 for the treatment of multiple myeloma.

• I-Mab Biopharma Announces New CFO

  8/1/2018

  On August 1, 2018 Beijing time, I-Mab Biopharma announced the appointment of Jielun Zhu as Chief Financial Officer (CFO). Mr. Zhu will report directly to Dr. Jingwu Zang, Chairman and CEO of I-Mab.

• ABL Bio and I-Mab Biopharma Announce Global Collaboration on Innovative Bispecific Antibodies

  7/30/2018

  I-Mab and ABL Bio will collaborate on three novel Bispecific Antibodies (BsAbs) while ABL Bio is licensing additional I-Mab antibody sequences for development using ABL Bio's BsAb platform.

• I-Mab Biopharma and ABL Bio Announce Global Collaboration on Innovative Bispecific Antibodies

  7/26/2018

  I-Mab Biopharma and ABL Bio Corporation jointly announced that two companies had entered into a strategic partnering agreement for ABL Bio to in-license the global rights excluding Greater China to I-Mab's bispecific antibodies

• I-Mab Biopharma Signs Licensing Agreement for HyLeukin With Genexine

  12/27/2017

  Under the terms of the agreement, I-Mab will provide an upfront payment in exchange for an exclusive license for development and commercialization rights of HyLeukin in greater China in the field of oncology.